Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent MRI lesions after first-line treatment.
Denise ObrechtLena SchömigMartin MynarekBrigitte BisonRudolf SchwarzTorsten PietschStefan M PfisterMartin SillDominik SturmFelix SahmRolf-Dieter KortmannNicolas U GerberAndré O von BuerenGudrun FleischhackUlrich SchüllerGunther NussbaumerMartin BeneschStefan RutkowskiPublished in: Neuro-oncology (2024)
Overall response and extent of lesions can function as surrogate parameters to predict outcomes in pediatric MB patients with persistent lesions after first-line therapy. Especially in case of solitary persistent medulloblastoma MRI lesion, additional therapy was not beneficial. Therefore, treatment response, extent/kind of residual lesions and further diagnostic information needs consideration for indication of additional treatments for persisting lesions.